<strike id="1rpfh"><dl id="1rpfh"><del id="1rpfh"></del></dl></strike>
<span id="1rpfh"><dl id="1rpfh"><strike id="1rpfh"></strike></dl></span>
<strike id="1rpfh"></strike>
<strike id="1rpfh"><dl id="1rpfh"></dl></strike>
<ruby id="1rpfh"><dl id="1rpfh"><del id="1rpfh"></del></dl></ruby>

A Message to U.S. Healthcare Professionals on Bristol Myers Squibb’s Response to COVID-19

March 13, 2020

Dear Healthcare Professional:

In light of the developing situation around coronavirus (COVID-19), we would like to share immediate action Bristol Myers Squibb is taking to support the health and well-being of patients, customers and employees during this time. As the medical community navigates this challenge together, our highest priority remains caring for patients. ?

Therefore, in an effort to reduce the risk of spread of the coronavirus we have decided to have all of our field medical representatives, sales representatives, Clinical Nurse Consultants and Value and Access employees work remotely, effective March 13, 2020. Although we are limiting in person field interactions to business critical meetings only, our field medical, sales, clinical nurse consultants and value and access teams will continue to support your needs virtually, should you need Patient Support Resources and/or information regarding our products. These changes are intended to be temporary and we will continue to monitor and assess the situation.

It is our hope that these actions will help us continue to meet your practice’s needs for information and patient access to our medications, while supporting containment of the coronavirus. Importantly, we want to assure you that our medicines remain readily available through all standard channels and as the situation evolves, we will provide information to you as quickly as possible. You can reach out to your local representative, 1-800-332-2056 or Contact Us for information regarding Bristol Myers Squibb products.

Thank you for your partnership in our shared mission of caring for patients and our communities. We have confidence that together we all will effectively manage through this very challenging situation.


Adam Lenkowksky
SVP, General Manager U.S. Cardiovascular, Immunology and Oncology

Winselow Tucker
SVP, General Manager, U.S. Hematology

Awny Farajallah, MD, FACP
Vice President, U.S. Medical

Teng Ong, MD
Vice President, U.S. Hematology?

More on Our Response